CD79b is a component of a B-cell receptor restricted to mature B cells (except plasma cells) that is
expressed in a wide variety of B-cell malignancies.

The antibody-drug conjugate polatuzumab vedotin (DCDS4501A) consists of a protein directed
against CD79b via a protease-cleavable peptide linker maleimidocaproylvaline-citrulline-p-
disrupting agent, monomethyl auristatin E (MMAE), conjugated to a monoclonal antibody directed
at CD79b. Patients with relapsed/refractory (R/R) B-cell NHL at doses ≥ 1.8 mg/kg achieved Clinical
Companion Slide 1: CD79b is a component of a B-cell receptor restricted to mature B cells (except plasma cells) that is expressed in a wide variety of B-cell malignancies.

**METHODS**

**Patient Characteristics and Treatment Details**

- Data as of September 16, 2013; median time of follow up was 12.3 months
- Updated results are presented from patients treated at 1.8 mg/kg and from the 2.4 mg/kg dose levels
- Thirty-three patients were treated at 1.8 mg/kg, 43 at 2.4 mg/kg and polatuzumab vedotin alone (5 patients; dose level 3), and 2 at 4 mg/kg
- Median age of 64 years (range 21−86 years)
- Six patients continue to receive study treatment

**Overall Safety**

- The polatuzumab vedotin + rituximab combination was well tolerated. The most common treatment-related AEs were peripheral neuropathy, neutropenia, hyperglycemia, and pyrexia.

**Pharmacokinetic and Pharmacodynamic Evaluations**

- Peripheral neuropathy was managed with dose delays and dose reductions.

**Pharmacokinetics**

- Dose discontinuation, n (%)
- Patients who received ≥ 1 dose of study treatment and had ≥ 1 on-treatment tumor assessment. Disease measured by revised IWG criteria.

**Pharmacodynamics**

- Objective Response, n (%)
- Complete Response (CR)
- Partial Response (PR)
- Stable Disease (SD)
- Progression Disease (PD)

**Pharmacodynamic - Anti-Tumor Responses Observed by Lymphoma Subtypes ≥ 1.8 mg/kg**

- DLBCL: Single-Agent + Combo Polatuzumab Vedotin
- Mantle cell lymphoma
- Follicular lymphoma
- Small lymphocytic lymphoma
- Marginal zone lymphoma
- Burkitt lymphoma
- Others

**Clinical Activity/Efficacy**

- Overall objective responses were observed in 24/45 (53%) polatuzumab vedotin and 6/11 (55%) polatuzumab vedotin + rituximab patients

**Figures**

- Figure 1: Polatuzumab Vedotin Mechanism of Action
- Figure 2: Treatment-Emergent AEs in ≥ 10% of Patients (1.8 and 2.4 mg/kg)
- Figure 3: Time to First Onset of Peripheral Neuropathy
- Figure 4: Cycle 1/4 M/E Profiles after Polatuzumab Vedotin Administration (4.0 mg/kg)
- Figure 5: Polatuzumab Vedotin Anti-Tumor Responses Observed by Lymphoma Subtypes ≥ 1.8 mg/kg

**REFERENCES**


**ACKNOWLEDGMENTS**

- Developmental support provided for this poster